MINT-CLONIDINE TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CLONIDINE HYDROCHLORIDE

Saadav alates:

MINT PHARMACEUTICALS INC

ATC kood:

C02AC01

INN (Rahvusvaheline Nimetus):

CLONIDINE

Annus:

0.1MG

Ravimvorm:

TABLET

Koostis:

CLONIDINE HYDROCHLORIDE 0.1MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

CENTRAL ALPHA-AGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0108891001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2017-03-15

Toote omadused

_Page 1 of 29_
PRODUCT
MONOGRAPH
PR
MINT-CLONIDINE
Clonidine Hydrochloride Tablets, USP
0.1 mg and 0.2 mg
Antihypertensive
Mint Pharmaceuticals Inc.
1093 Meyerside Drive, Unit #1
Mississauga, Ontario
L5T 1J6
Date of Preparation:
MARCH 8, 2017
Submission Control No: 184607
_Page 2 of 29_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................................
4
ADVERSE REACTIONS
...............................................................................................................
7
DRUG INTERACTIONS
...............................................................................................................
9
DOSAGE AND ADMINISTRATION
.........................................................................................
11
OVERDOSAGE
...........................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
13
STORAGE AND STABILITY
.....................................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 15
PART II: SCIENTIFIC INFORMATION
..................................................................................
16
PHARMACEUTICAL INFORMATION
.....................................................................................
16
CLINICAL TRIALS
..............................................